Ad
related to: aranesp injection dosage instructions for patients with pneumoniagoodrx.com has been visited by 100K+ users in the past month
"About 50% of US physicians advise patients consult GoodRx." - Fortune
- GoodRx®: Women’s Health
Save on Common Women’s Health Meds.
Find Resources You Can Count On.
- Our Social Impact Mission
At GoodRx, values matter. Visit us
to see how we make a difference.
- Do I Need Insurance?
No! Compare Our Prices to Your
Insurance & Get the Biggest Savings
- Healthcare Professionals
GoodRx® Can Help You Get Major
Savings For Your Patients
- GoodRx®: Women’s Health
Search results
Results from the WOW.Com Content Network
Darbepoetin is marketed by Amgen under the trade name Aranesp. The medication was approved in September 2001, by the US Food and Drug Administration for treatment of anemia in patients with chronic kidney failure by intravenous or subcutaneous injection. [ 4 ]
[49] [50] Additional pneumococcal vaccine research is taking place to find a vaccine that offers broad protection against pneumococcal disease. [51] As of 2017, pneumonia vaccines target up to 23 forms of the bacterium that cause pneumonia with a new version under development covering 72 strains of the bacterium. [52] [needs update]
They are given by injection. [2] Common side effects may include joint pain, rash, vomiting, and headache. [4] Serious side effects may include heart attacks, stroke, increased cancer growth, or pure red cell aplasia. [2] It is unclear if use is safe during pregnancy. [5] [6] They work similar to naturally occurring erythropoietin. [1]
Prevnar vaccine. Prevnar 20 (PCV20) is the third version of a vaccine produced by the Wyeth subsidiary of Pfizer.In April 2023, the FDA approved Prevnar 20 for the prevention of invasive disease caused by the 20 different serotypes of S. pneumoniae contained in the vaccine (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F) for individuals 6 ...
The most common adverse reactions (reported in more than 10% of subjects vaccinated with pneumococcal polysaccharide vaccine in clinical trials) were: pain, soreness or tenderness at the site of injection (60.0%), injection-site swelling or temporary thickening or hardening of the skin (20.3%), headache (17.6%), injection-site redness (16.4%), weakness and fatigue (13.2%), and muscle pain (11.9%).
Common side effects include high blood pressure, headache, disabling cluster migraine (resistant to remedies), joint pain, and clotting at the injection site. Rare cases of stinging at the injection site, skin rash, and flu-like symptoms (joint and muscle pain) have occurred within a few hours following administration.
In February 2023, results of a phase III study of around 25,000 participants age 60+ were published. One dose of the Arexvy vaccine provided 94% efficacy against severe RSV pneumonia and 72% efficacy against RSV acute respiratory infection. [32] An advisory panel to the FDA recommended approval of the vaccine in February 2023. [33] [34]
Pneumococcal infection is an infection caused by the bacterium Streptococcus pneumoniae. [1]S. pneumoniae is a common member of the bacterial flora colonizing the nose and throat of 5–10% of healthy adults and 20–40% of healthy children. [2]